Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 May;47(5):659–669. doi: 10.1038/bjc.1983.104

Modification of CCNU pharmacokinetics by misonidazole--a major mechanism of chemosensitization in mice.

F Y Lee, P Workman
PMCID: PMC2011404  PMID: 6849803

Abstract

We have investigated the effect of misonidazole (MISO) on the pharmacokinetics of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in mice. CCNU and its monohydroxylated metabolites were measured using a high performance liquid chromatography (HPLC) method. In the absence of MISO the plasma disappearance of CCNU was biphasic with a t 1/2 alpha of 2.3 min and a t 1/2 beta of 53 min. The monohydroxylated metabolites of CCNU also followed biphasic clearance kinetics. A large single dose of MISO (0.5 mg g-1), given i.p. 30 min prior to CCNU, prolonged the t 1/2 alpha by a factor of 2.6 but had no effect on t 1/2 beta. In addition, the apparent volume of distribution was decreased by a factor of 1.6. Consequently, the plasma area under the curve (AUC0 - infinity) was increased by a factor of 1.7 for CCNU and by a factor of 2.0 for total nitrosourea (CCNU + monohydroxylated metabolites). The effects of MISO on CCNU kinetics were dependent on MISO dose and plasma concentration and on the interval between MISO and CCNU administration. The concentration of CCNU was measured in 4 tumours: the KHT, RIF-1 and EMT6 mouse tumours, and the HT29 xenograft. For all 4 tumours, 0.5 mg g-1 MISO raised the tumour concentrations of CCNU and total nitrosourea by a considerable amount (2-2.5 times). More detailed studies in the KHT tumour demonstrated that there was a significant lag period before peak tumour CCNU concentrations were reached, and that MISO increased the peak concentrations by a factor of about 2.4. In contrast, there was no such lag period for the plasma and MISO did not increase the plasma peak CCNU concentrations. These data strongly suggest that modification of the pharmacokinetics may be a major contributory factor in the enhancement of CCNU cytotoxicity by large single doses of MISO in vivo.

Full text

PDF
659

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown J. M., Hirst D. G. Effect of clinical levels of misonidazole on the response of tumour and normal tissues in the mouse to alkylating agents. Br J Cancer. 1982 May;45(5):700–708. doi: 10.1038/bjc.1982.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brown J. M. The mechanisms of cytotoxicity and chemosensitization by misonidazole and other nitroimidazoles. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):675–682. doi: 10.1016/0360-3016(82)90711-8. [DOI] [PubMed] [Google Scholar]
  3. Clutterbuck R. D., Millar J. L., McElwain T. J. Misonidazole enhancement of the action of BCNU and melphalan against human melanoma xenografts. Am J Clin Oncol. 1982 Feb;5(1):73–78. [PubMed] [Google Scholar]
  4. Gomer C. J., Johnson R. J. Relationship between misonidazole toxicity and core temperature in C3H mice. Radiat Res. 1979 May;78(2):329–333. [PubMed] [Google Scholar]
  5. Hilton J., Walker M. D. Hydroxylation of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea. Biochem Pharmacol. 1975 Dec 1;24(23):2153–2158. doi: 10.1016/0006-2952(75)90045-3. [DOI] [PubMed] [Google Scholar]
  6. Hirst D. G., Brown J. M., Hazlehurst J. L. Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain. Br J Cancer. 1982 Jul;46(1):109–116. doi: 10.1038/bjc.1982.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. McNally N. J. Enhancement of chemotherapy agents. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):593–598. doi: 10.1016/0360-3016(82)90691-5. [DOI] [PubMed] [Google Scholar]
  8. Millar B. C. Hypoxic cell radiosensitizers as potential adjuvants to conventional chemotherapy for the treatment of cancer. Biochem Pharmacol. 1982 Aug 1;31(15):2439–2445. doi: 10.1016/0006-2952(82)90051-x. [DOI] [PubMed] [Google Scholar]
  9. Montgomery J. A., Johnston T. P., Thomas H. J., Piper J. R., Temple C., Jr The use of microparticulate reversed-phase packing in high-pressure liquid chromatography of compounds of biological interest. Adv Chromatogr. 1977;15:169–195. [PubMed] [Google Scholar]
  10. Mulcahy R. T. Chemical properties of nitrosoureas: implications for interaction with misonidazole. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):599–602. doi: 10.1016/0360-3016(82)90692-7. [DOI] [PubMed] [Google Scholar]
  11. Mulcahy R. T., Siemann D. W., Sutherland R. M. In vivo response of KHT sarcomas to combination chemotherapy with radiosensitizers and BCNU. Br J Cancer. 1981 Jan;43(1):93–99. doi: 10.1038/bjc.1981.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Shoemaker D. D., McManus M. E., Hoerauf R., Strong J. M. Studies on the O-demethylation of misonidazole by rat liver microsomes. Cancer Treat Rep. 1982 Jun;66(6):1343–1347. [PubMed] [Google Scholar]
  13. Siemann D. W. In vivo combination of misonidazole and the chemotherapeutic agent CCNU. Br J Cancer. 1981 Mar;43(3):367–377. doi: 10.1038/bjc.1981.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Siemann D. W. Potentiation of chemotherapy by hypoxic cell radiation sensitizers--a review. Int J Radiat Oncol Biol Phys. 1982 Jun;8(6):1029–1034. doi: 10.1016/0360-3016(82)90172-9. [DOI] [PubMed] [Google Scholar]
  15. Siemann D. W. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers. Br J Cancer. 1982 Feb;45(2):272–281. doi: 10.1038/bjc.1982.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tannock I. F. In vivo interaction of anti-cancer drugs with misonidazole or metronidazole: cyclophosphamide and BCNU. Br J Cancer. 1980 Dec;42(6):871–880. doi: 10.1038/bjc.1980.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Twentyman P. R., Kallman R. F., Brown J. M. The effect of time between X-irradiation and chemotherapy on the growth of three solid mouse tumors--I. Adriamycin. Int J Radiat Oncol Biol Phys. 1979 Aug;5(8):1255–1260. doi: 10.1016/0360-3016(79)90649-7. [DOI] [PubMed] [Google Scholar]
  18. Twentyman P. R., Workman P. An investigation of the possibility of chemosensitization by clinically achievable concentrations of misonidazole. Br J Cancer. 1983 Feb;47(2):187–194. doi: 10.1038/bjc.1983.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Twentyman P., Workman P. Effect of misonidazole or metronidazole pretreatment on the response of the RIF-1 mouse sarcoma to melphalan, cyclophosphamide, chlorambucil and CCNU. Br J Cancer. 1982 Mar;45(3):447–455. doi: 10.1038/bjc.1982.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Walker M. D., Hilton J. Nitrosourea pharmacodynamics in relation to the central nervous system. Cancer Treat Rep. 1976 Jun;60(6):725–728. [PubMed] [Google Scholar]
  21. Warenius H. M., Bleehen N. M. In vivo-in vitro clonogenic assays in a human tumour xenograft with a high plating efficiency. Br J Cancer. 1982 Jul;46(1):45–50. doi: 10.1038/bjc.1982.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wheeler G. P., Johnston T. P., Bowdon B. J., McCaleb G. S., Hill D. L., Montgomery J. A. Comparison of the properties of metabolites of CCNU. Biochem Pharmacol. 1977 Dec 15;26(24):2331–2336. doi: 10.1016/0006-2952(77)90436-1. [DOI] [PubMed] [Google Scholar]
  23. White R. A., Workman P., Freedman L. S., Owen L. N., Bleehen N. M. The pharmacokinetics of misonidazole in the dog. Eur J Cancer. 1979 Oct;15(10):1233–1242. doi: 10.1016/0014-2964(79)90249-4. [DOI] [PubMed] [Google Scholar]
  24. White R. A., Workman P. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs. Br J Cancer. 1980 Feb;41(2):268–276. doi: 10.1038/bjc.1980.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Workman P., Brown J. M. Structure-pharmacokinetic relationships for misonidazole analogues in mice. Cancer Chemother Pharmacol. 1981;6(1):39–49. doi: 10.1007/BF00253009. [DOI] [PubMed] [Google Scholar]
  26. Workman P. Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice. Cancer Chemother Pharmacol. 1980;5(1):27–37. doi: 10.1007/BF00578559. [DOI] [PubMed] [Google Scholar]
  27. Workman P., Little C. J., Marten T. R., Dale A. D., Ruane R. J., Flockhart I. R., Bleehen N. M. Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography. J Chromatogr. 1978 May 1;145(3):507–512. doi: 10.1016/s0378-4347(00)81386-9. [DOI] [PubMed] [Google Scholar]
  28. Workman P. Pharmacokinetics of hypoxic cell radiosensitizers: a review. Cancer Clin Trials. 1980 Fall;3(3):237–251. [PubMed] [Google Scholar]
  29. Workman P., Twentyman P. R. Enhancement by electron-affinic agents of the therapeutic effects of cytotoxic agents against the KHT tumor: structure-activity relationships. Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):623–626. doi: 10.1016/0360-3016(82)90698-8. [DOI] [PubMed] [Google Scholar]
  30. Workman P., Twentyman P. R., Lee F. Y., Walton M. I. Drug metabolism and chemosensitization. Nitroimidazoles as inhibitors of drug metabolism. Biochem Pharmacol. 1983 Mar 1;32(5):857–864. doi: 10.1016/0006-2952(83)90588-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES